Vital KSK HoldingsVITAL KSK HOLDINGS,INC.3151東証プライム卸売業FY ending Mar 2026, consolidated, J-GAAP

Vital KSK Holdings FY ending Mar 2026 results

About 94% of Vital KSK Holdings's sales come from Medicine wholesale, with Pharmacy Business and Veterinary drugs wholesale business making up much of the rest.

Out of every ¥100 of sales, about ¥1 is left as operating profit.

Revenue changed +1.7% from the prior year, operating profit -29.4%.

Revenue and profit pattern

Revenue up, profit downRevenue grew faster

Revenue +1.7% · profit -29.4%, calculated from disclosed figures.

Operating leverage: -17.44× (profit growth ÷ revenue growth)

What changed from last year

FY ending Mar 2025 → FY ending Mar 2026

Revenue: +1.7%¥600.4B → ¥610.5B
Gross profit: +0.7%¥49.2B → ¥49.6B
Operating income: -29.4%¥5.71B → ¥4.03B
Net income attributable to owners: +0.7%¥7.31B → ¥7.36B
Operating cash flow: Back to profit-¥8.02B → ¥4.83B
Free cash flow: Loss-¥12.4B → -¥435M

Results at a glance

Revenue for the FY ending Mar 2026 was ¥610.5B, up +1.7% from ¥600.4B.
Gross profit barely moved (+0.7%, to ¥49.6B), while operating income dropped -29.4%, from ¥5.71B to ¥4.03B.
Net income still edged up +0.7% to ¥7.36B.
Operating cash flow swung back to a positive ¥4.83B after -¥8.02B the year before.

What drove the change

Sales grew as the company pushed newer drugs, mainly cancer treatments, and flu vaccines
Higher prices raised logistics and IT costs, lifting SG&A
The newly launched drug-development business booked R&D costs with no sales yet, so it ran at a loss
Competitive bidding in parts of the Kinki region cut sales and profit at KSK
Gains from selling investment securities kept net income level with the prior year

Things to watch

Official drug prices are now cut almost every year, and changes to the insurance system can hit results
Drug makers can change the rebates and sales incentives they pay wholesalers
Aggressive price competition from rivals in some regions could push selling prices down

Annual Securities Report / 経営者による財政状態、経営成績及びキャッシュ・フローの状況の分析 · Annual Securities Report / 事業等のリスク

Where the money goes

FY ending Mar 2025 → FY ending Mar 2026

Where ¥100 of sales goes

For every ¥100 Vital KSK Holdings sells, how much goes where, and how much is kept.

FY ending Mar 2026

Cost of sales: ¥92
SG&A: ¥7
Operating profit: ¥1
Net profit kept: ¥1

Annual margin trends

Gross margin8.1%

Operating margin0.7%

Net margin1.2%

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Which businesses earn the money

Revenue by business segment, and the profit each one keeps.

FY ending Mar 2026

Medicine wholesale¥572.9B
94%
Op. margin 0.9%Industry: Specialty Trading & Wholesale
Pharmacy Business¥20B
3%
Op. margin 1.3%Industry: Drugstores & Pharmacies
Veterinary drugs wholesale business¥12.6B
2%
Op. margin 2.4%Industry: Pets
Nursing Care-related Rental and Other Business¥5.05B
1%
Op. margin -2.0%Industry: Nursing Care

Profit by segment

※ Segment figures include inter-segment sales and do not sum to the company total

Sources

Show source documents (6)

EDINET (FSA Japan)
有価証券報告書－第17期(2025/04/01－2026/03/31)
ID S100YDSN2026-06-19Open
EDINET (FSA Japan)
訂正有価証券報告書－第16期(2024/04/01－2025/03/31)
ID S100WBYI2025-07-09Open
EDINET (FSA Japan)
有価証券報告書－第15期(2023/04/01－2024/03/31)
ID S100TV6K2024-06-27Open
EDINET (FSA Japan)
訂正有価証券報告書－第14期(2022/04/01－2023/03/31)
ID S100RAXF2023-06-30Open
EDINET (FSA Japan)
有価証券報告書－第13期(令和3年4月1日－令和4年3月31日)
ID S100OJBQ2022-06-29Open
EDINET (FSA Japan)
有価証券報告書－第12期(令和2年4月1日－令和3年3月31日)
ID S100LP2Z2021-06-28Open

Extracted from XBRL: 56 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open Markdown Share on X Save image